Highly potent EGFR and ErbB2 inhibitor; inhibts wild type and mutated receptors
JBJ-03-142-02 is a highly potent epidermal growth factor receptor (EGFR) and ErbB2 (human epidermal growth factor receptor; HER2) inhibitor. Inhibits wild type and tumorgenic mutated receptors (exon 20 insertion; Ex20Ins). Antiproliferative
in vitro
(IC50 values are 7.6, 30 - 95, 3.8 and 19 - 31 nM for Ba/F3 cells expressing wild type EGFR, EGFR with Ex20Ins mutation, wild type HER2 and HER2 with Ex20Ins mutation, respectively). Also inhibits other common EGFR mutants. Antiproliferative in patient-derived lung cancer cell lines.
| Marque | Tocris |
|---|---|
| Réf. B-LABO | BL-RE-151455 |
| Réf. fabricant | 18768496 |
| Nom chimique ou matériau | (4-Fluorophenyl)methyl N-[2-[(1-methyl-1 H-pyrazol-4-yl)amino]-4-pyrimidinyl]-N-[3-[(1-oxo-2-propen-1-yl)amino]phenyl]carbamate |
| CAS | 2068806-31-3 |
| Quantité | 10 mg |
| Cible | EGF Receptor Inhibitors |
| Formule moléculaire | C<sub>25</sub>H<sub>22</sub>FN<sub>7</sub>O<sub>3</sub> |
| Poids de la formule | 2323 |
| Pureté | 98% |
